Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Advancements in Understanding the Hide-and-Seek Strategy of Hibernating Breast Cancer Cells and Their Implications in Oncology from a Broader Perspective: A Comprehensive Overview.
Al-Ruwishan A, Amer B, Salem A, Abdi A, Chimpandu N, Esa A, Melemenis A, Saleem MZ, Mathew R, Gamallat Y. Al-Ruwishan A, et al. Among authors: esa a. Curr Issues Mol Biol. 2024 Aug 1;46(8):8340-8367. doi: 10.3390/cimb46080492. Curr Issues Mol Biol. 2024. PMID: 39194709 Free PMC article. Review.
Inflammatory myofibroblastic tumor of the prostate.
Fukiage K, Fujita K, Toyoda S, Nishimoto M, Kikuchi T, Chikugo T, Yoshimura K, Esa A, Ito A, Uemura H. Fukiage K, et al. Among authors: esa a. IJU Case Rep. 2024 Jan 18;7(2):141-143. doi: 10.1002/iju5.12687. eCollection 2024 Mar. IJU Case Rep. 2024. PMID: 38440704 Free PMC article.
Prognosis of Patients Receiving Chemotherapy for Metastatic Upper Tract Urothelial Carcinoma Compared With Metastatic Urinary Bladder Cancer.
Adomi S, Fujita K, Kita H, Kuwahara K, Akashi Y, Nishimoto M, Matsumura N, Sugimoto K, Minami T, Nozawa M, Yoshimura K, Tahara H, Hirayama A, Nishioka T, Esa A, Uemura H. Adomi S, et al. Among authors: esa a. Cancer Diagn Progn. 2023 Jul 3;3(4):484-490. doi: 10.21873/cdp.10244. eCollection 2023 Jul-Aug. Cancer Diagn Progn. 2023. PMID: 37405216 Free PMC article.
Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis.
Matsumura N, Fujita K, Nishimoto M, Yamamoto Y, Kuwahara K, Nagai Y, Minami T, Hatanaka Y, Nozawa M, Morimoto Y, Tahara H, Uejima S, Esa A, Hirayama A, Yoshimura K, Uemura H. Matsumura N, et al. Among authors: esa a. Front Oncol. 2021 Dec 21;11:769068. doi: 10.3389/fonc.2021.769068. eCollection 2021. Front Oncol. 2021. PMID: 34993133 Free PMC article.
Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients - A propensity scoring approach.
Nagao K, Matsuyama H, Nozawa M, Hara I, Nishioka T, Komura T, Esa A, Uejima S, Imanishi M, Uekado Y, Ogawa T, Kajikawa H, Uemura H. Nagao K, et al. Among authors: esa a. Asian J Urol. 2016 Jan;3(1):33-38. doi: 10.1016/j.ajur.2015.10.003. Epub 2015 Oct 31. Asian J Urol. 2016. PMID: 29264160 Free PMC article.
108 results